Zobrazeno 1 - 10
of 710
pro vyhledávání: '"Sattva S Neelapu"'
Autor:
Michael Green, Jingwei Liu, Zheng Zhang, Fuliang Chu, Sattva S Neelapu, Laura Bover, Ryan Sun, Jingjing Cao, Haopeng Yang, Timothy J Davis, Shao-qing Kuang, Xiaoyun Cheng, Swathi Karri, Long T Vien, Francisco Vega, Richard Eric Davis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent and durable effects in B-cell malignancies. However, antigen loss or downregulation is a frequent cause of resistance. Here, we report development of a novel CAR T-cell
Externí odkaz:
https://doaj.org/article/d33413c6c13241c5b627404f177fbf5d
Autor:
Frederick L Locke, Stephan A Grupp, Elizabeth J Shpall, Sattva S Neelapu, Michael R Bishop, Marcela V Maus, Jorg Dietrich, Daniel W Lee, Matthew J Frigault, Terry J Fry, Sara Alexander, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Julie C Fitzgerald, Jennifer L Holter-Chakrabarty, Krishna V Komanduri, Shannon L Maude, Philip L McCarthy, Elena Mead, Tomas G Neilan, Bianca D Santomasso, David T Teachey, Cameron J Turtle, Tom Whitehead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea
Externí odkaz:
https://doaj.org/article/d61d44366994471cbc391339ac6fd898
Autor:
Ronald Levy, Joshua Brody, David L Porter, Sattva S Neelapu, Koen Van Besien, Michael Werner, Michael R Bishop, Mitchell S Cairo, Sherry Adkins, Stephen M Ansell, Jonathan W Friedberg, Justin P Kline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, how
Externí odkaz:
https://doaj.org/article/2fb77ce0a5a54f93aaa50a040c2bdee0
Autor:
Dai Chihara, Michelle A Fanale, Roberto N Miranda, Mansoor Noorani, Jason R Westin, Loretta J Nastoupil, Fredrick B Hagemeister, Luis E Fayad, Jorge E Romaguera, Felipe Samaniego, Francesco Turturro, Hun J Lee, Sattva S Neelapu, M Alma Rodriguez, Michael Wang, Nathan H Fowler, Richard E Davis, L Jeffrey Medeiros, Yasuhiro Oki
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0191461 (2018)
We performed a retrospective analysis to identify risk factors and survival outcome for central nervous system (CNS) relapse of peripheral T-cell lymphoma (PTCL) by histologic type. Records of 600 PTCL patients diagnosed between 1999 and 2014 were an
Externí odkaz:
https://doaj.org/article/73ceca117ba94c9caecbd4ff828737e7
Autor:
Zheng Chen, Eric F Pittman, Jorge Romaguera, Luis Fayad, Michael Wang, Sattva S Neelapu, Peter McLaughlin, Larry Kwak, Nami McCarty
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e69126 (2013)
BACH2, a B-cell specific transcription factor, plays a critical role in oxidative stress-mediated apoptosis. Bortezomib (Velcade(TM)) is widely used to treat relapsed mantle cell lymphoma (MCL) patients despite varying clinical outcomes. As one of th
Externí odkaz:
https://doaj.org/article/bbf89d35ed8d4a93a3ef1cf95d70705c
Autor:
Zaid Abdel Rahman, Syed Ali Abutalib, Aimaz Afrough, Sairah Ahmed, Taha Al-Juhaishi, Amin M Alousi, Leonard C. Alsfeld, Farrukh T. Awan, Ahsan Azhar, Qaiser Bashir, Brandon Douglas Brown, Kai Cao, Richard E. Champlin, Hua-Jay J. Cherng, Stefan O. Ciurea, Bouthaina Dabaja, May Daher, Marcos De Lima, Christen M. Dillard, Penny Fang, Marcelo A. Fernández Viña, Christopher James Ferreri, Fateeha Furqan, Nico Gagelmann, Praveen Ramakrishnan Geethakumari, Sassine Ghanem, Uri Greenbaum, Alison M. Gulbis, Ali Haider, Mehdi Hamadani, Victoria Wehr Handy, Misha C. Hawkins, Ella J. Ariza Heredia, Chitra Hosing, Jin Seon Im, Nitin Jain, Andrew P Jallouk, Mika L. Jankowski, Brandon J. Kale, Partow Kebriaei, Lana Khalil, Irum Khan, Sajad Khazal, Piyanuch Kongtim, Paul Lin, Kris M. Mahadeo, Alexandre E Malek, Kara McGee, Rohtesh S. Mehta, Victor Eduardo Mulanovich, Pashna N. Munshi, Loretta J. Nastoupil, Sattva S Neelapu, Yago Nieto, Amanda Olson, Betul Oran, Folashade Otegbeye, Akshat Maneesh Patel, Krina Patel, Prince Paul, Naveen Pemmaraju, Uday R Popat, Muzaffar H. Qazilbash, Hind Rafei, Dristhi S Ragoonanan, Jeremy L. Ramdial, Katayoun Rezvani, Ana Avila Rodriguez, Gabriela Rondón, Supawee Saengboon, Gabriela Sanchez-Petitto, Terri Lynn Shigle, Elizabeth J. Shpall, Samer A. Srour, Raphael E. Steiner, Karen R. Stolar, Paolo Strati, Nicholas A. Szewczyk, Mark R. Tanner, Kevin Tang, Peter F. Thall, Sudhakar Tummala, Chukwuemeka Uzoka, Whitney D. Wallis, Jason R. Westin, Nathaniel R. Wilson, Susan Wu, Eduardo Yepez Guevara, Jun Zou
Publikováno v:
Manual of Hematopoietic Cell Transplantation and Cellular Therapies ISBN: 9780323798334
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd4108048a50ce283e308d026c579bfa
https://doi.org/10.1016/b978-0-323-79833-4.00042-5
https://doi.org/10.1016/b978-0-323-79833-4.00042-5
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ebedb9cdef4e30b7e8b0e20978feb3
https://doi.org/10.1200/jco.22.01797
https://doi.org/10.1200/jco.22.01797
Autor:
Matthew A. Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Harry Miao, Shilpa Shahani, Anik R. Patel, Clare Spooner, Christine Fu, Hairong Xu, Marcelo C Pasquini
Publikováno v:
Blood. 140:1852-1855
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::803f69534c9fdf01d7e82f8a15796e3b
https://doi.org/10.1182/blood-2022-162421
https://doi.org/10.1182/blood-2022-162421
Autor:
Miriam T. Jacobs, Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph McGuirk, Abhinav Deol, Alison Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C. Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:753-759
The majority of patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, develop cytokine release syndrome (CRS). Whether the lack of development of CRS with axi-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4df67cd9619f066605f7a15d48450a1
https://doi.org/10.1016/j.clml.2022.05.004
https://doi.org/10.1016/j.clml.2022.05.004
Autor:
Hua‐Jay J. Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Maria Rodriguez, Michael Wang, Fredrick Hagemeister, Chelsea C. Pinnix, Jeremy Ramdial, Samer Srour, Yago Nieto, Katayoun Rezvani, Richard Champlin, Partow Kebriaei, Jason Westin, Homer A. Macapinlac, Elizabeth Shpall, Sairah Ahmed
Publikováno v:
British Journal of Haematology. 200:35-44
Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc3a2f0e340856ad0d00934140b2d10
https://doi.org/10.1111/bjh.18441
https://doi.org/10.1111/bjh.18441